Duchenne News Tags: PepGen

October 17, 2023
PepGen shares Q3 updates via newsletter summary.
July 21, 2023
PepGen shares their 2023 Q2 newsletter
May 19, 2023
PepGen announces clearance by Health Canada of CTA for PGN-EDO51 to begin the Phase 2 Clinical Trial, CONNECT1-EDO51
April 10, 2023
PepGen announces quarterly newsletter on April 7, 2023.
September 28, 2022
PepGen announces the completed results from its Phase 1 healthy normal volunteer (HNV) trial of PGN-EDO51 for Duchenne.

Accessible Vehicle Fund Applications Open